Amendments To Australia’s Intellectual Property Laws

by FPA Patent Attorneys

On 19 March 2014, the Intellectual Property Laws Amendment Bill 2014 (Cth) (the Bill) was introduced into parliament.

Most substantively, the Bill seeks to introduce a compulsory licensing scheme for pharmaceuticals and to take steps to unify the Australian and New Zealand patent examination regimes. In principle, these proposals appear largely uncontroversial. At a policy level, providing a mechanism to facilitate the supply of pharmaceuticals to foreign countries in need seems entirely reasonable. The proposed steps to unify the Australian and New Zealand patent examination regimes also seem reasonable — at least from the perspective that the agreement between Australia and New Zealand to actually do so has, it seems, already been made.

As always, however, it will be interesting to see how well the proposed amendments actually achieve these goals, and whether any unintended consequences ensue.

Overview of proposed amendments

At a high level, the Bill proposes amendments to:

  • the Patents Act 1990 (Cth) to introduce compulsory pharmaceutical licensing provisions in compliance with the TRIPS Protocol (Schs 1 and 2);
  • the Plant Breeder’s Rights Act 1994 (Cth) to provide the Federal Circuit Court with jurisdiction over infringement matters (Sch 3);
  • facilitate a unified Australia and New Zealand patent attorney profession and patent filing and examination processes (Sch 4); and
  • remove document retention provisions and correct errors arising from the last amendments made to the Patents Act (Sch 5).

Arguably, the most substantive proposals are those in respect of compulsory pharmaceutical licensing and unification of the patent attorney profession and patent prosecution for Australia and New Zealand.

Compulsory licensing provisions in respect of pharmaceuticals

In 2005, theWorld Trade Organization Agreement on Trade-Related Aspects of Intellectual Property Rights (the TRIPS Agreement) was amended to introduce compulsory licence provisions in respect of pharmaceuticals. At a general level, these provisions provide for compulsory patent licences for the purposes of manufacturing and exporting vital medicines to countries in need.

As stated in the Explanatory Memorandum (the EM) to the Bill:

The Aim of the Protocol is to encourage patent owners to either practice price differentiation, and provide medicines to least developed and developing countries in need at affordable prices, or to issue voluntary licences to generic manufactures to provide medicines at affordable prices. If a patent owner is unwilling to do this, then the Protocol provides a mechanism to force the patent owner to issue a compulsory licence.1

Australia is a signatory to the TRIPS Agreement. However, it is yet to comply with its obligations in this regard.

A broad objective considered in the lead-up to the Bill was that of providing countries in need with medicines while at the same time supporting innovation and maintaining current expenditure on foreign aid (compliance with the TRIPS Agreement was not itself an objective). The options considered to meet the objective were to:

  1. take no action;
  2. give the Federal Court power to grant and amend licences;
  3. give the Commissioner of Patents power to grant and amend licences; and
  4. increase funding for relevant aid programs.

On their face, options (1) and (4) do not appear to meet the objective, so it is perhaps unsurprising that they were not recommended. Based on government and public consultations, conferring the power to grant a compulsory licence on the Federal Court was found more palatable than conferring such power on the Commissioner of Patents, leading to option (2) being recommended.

Against this background, Schs 1 and 2 of the Bill propose amendments that allow an application to be made to the Federal Court for an order requiring the patentee of a patented pharmaceutical invention (PPI) to 78 intellectual property law bulletin April 2014 grant a compulsory licence to exploit the invention “to the extent necessary for the purpose of manufacturing a pharmaceutical product in Australia for export to an eligible importing country”.

If implemented, these provisions will expand Australia’s existing compulsory licence provisions, which provide the Federal Court with power to grant a compulsory licence where the reasonable requirements of the public with respect to a patented invention have not been satisfied or where a patent owner contravenes the restrictive trade practices provisions of Australia’s Competition and Consumer Act 2010 (Cth).

Australia and New Zealand Single Economic Market initiative

Australia and New Zealand have a long history of cooperation in economic and trade relationships. This history has seen the progressive integration of policies, laws and regulatory regimes — with the most recent initiative being to create a seamless trans-Tasman business environment: the Single Economic Market (SEM) initiative.

In pursuit of the SEM initiative, Sch 4 of the Bill proposes two broad changes: the implementation of a trans-Tasman patent attorney regime and the provision of a more unified approach to patent filing and examination.

Australia and New Zealand patent attorneys

In 2013, Australia and New Zealand agreed to establish a single regulatory regime for patent attorneys. New Zealand has agreed that the framework will be based on Australia’s existing regulatory regime. Consequently, the amendments proposed in the Bill focus on administrative facilitation rather than substantive changes to the requirements and procedures governing the Australian patent attorney profession.

To facilitate the trans-Tasman regulatory regime for patent attorneys, the Bill proposes amendments that create a unified registration process, register, code of conduct, disciplinary process, and regulatory bodies for Australian and New Zealand patent attorneys.

Patent applications and examination

Turning to patent filing and examination, the Bill puts forward amendments to allow Australian patent applica tions to be filed at and examined by the New Zealand patent office.

Fundamentally, this is achieved by amending the Patents Act to allow the Australian Commissioner of Patents to delegate “any or all” of the Commissioner’s powers and functions to a New Zealand patent official. Under this approach, the intention is that existing administrative and judicial review procedures will remain available irrespective of whether an Australian or a New Zealand patent office official makes a decision.

New Zealand has also made changes to facilitate the SEM initiative. Under the Patents Act 2013 (NZ), many aspects of New Zealand patent law have been aligned (at least at the legislative level) with Australian patent law.This includes procedural conformity in a number of areas (such as the manner in which examination proceeds, when patent publication occurs, and the ability to request re-examination of a patent), as well as alignment in several substantive areas (such as the prior art base, utility requirements and support requirements).

The conformity is not, however, universal. For example, at the fundamental level of what constitutes patent-eligible subject matter, the only express exclusion under Australian legislation (for standard patent applications) is human beings and biological processes for their generation. In addition to this exclusion, however, New Zealand legislation excludes methods of diagnosis practised on humans, plant varieties, computer programs “as such”, and methods of treating humans by surgery or therapy. Contrasting with the last of these exclusions is Australia’s 2013 High Court decision of Apotex Pty Ltd v Sanofi-Aventis Australia Pty Ltd,2 in which the ability to patent methods of medical treatment was confirmed.

1 Explanatory Memorandum to the Intellectual Property Laws Amendment Bill 2014 (Cth), p 10 at [12].

2 Apotex Pty Ltd v Sanofi-Aventis Australia Pty Ltd (2013) 304 ALR 1; 103 IPR 217; [2013] HCA 50; BC201315312.

This article was first published in LexisNexis' Australian Intellectual Property Law Bulletin, vol. 27, no. 3, 2014.

Written by:

FPA Patent Attorneys

FPA Patent Attorneys on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at:

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.